Skip to main content
SpringerLink
Log in

Biology of Giant Cell Tumour

  • Chapter
  • First Online:
Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions

  • 1228 Accesses

Abstract

Giant cell tumour of bone (GCTb) is a locally aggressive osteolytic tumour. Approximately 5% of GCTb develop pulmonary metastases. Although many studies proposed agents targeting osteoclast differentiation and bone resorption, identification of tissue and circulating biomarkers may improve the prediction of malignant progression, early differentiating high-risk patients prone to recive more appropiate therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Théoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Rédini F, Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol. 2009;21:338–44.

    Article  Google Scholar 

  2. Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res. 2010;468:827–33.

    Article  Google Scholar 

  3. Wittrant. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 2004;1704:49–57.

    CAS  PubMed  Google Scholar 

  4. Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone. 2013;52:238–46.

    Article  Google Scholar 

  5. Broadhead ML, Clark JC, Dass CR, Choong PF, Myers DE. Therapeutic targeting of osteoclast function and pathways. Expert Opin Ther Targets. 2011;15:169–81.

    Article  Google Scholar 

  6. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone. 2011;49:71–6.

    Article  CAS  Google Scholar 

  7. Heymann D. Anti-RANKL therapy for bone tumours. Basic, pre-clinical and clinical evidence. J Bone Oncol. 2012;1:2–11.

    Article  Google Scholar 

  8. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655–64.

    Article  CAS  Google Scholar 

  9. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97:887–92.

    Article  Google Scholar 

  10. Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone—a review and future management considerations. Curr Oncol. 2013;20:e442–7.

    Article  CAS  Google Scholar 

  11. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–71.

    Article  CAS  Google Scholar 

  12. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active controlled phase II study of denosumab efficacy and safety in patients with breast cancer–related bone metastases. J Clin Oncol. 2007;25:4431–7.

    Article  CAS  Google Scholar 

  13. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11:275–80.

    Article  CAS  Google Scholar 

  14. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012;18:4415–24.

    Article  CAS  Google Scholar 

  15. Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, Beltrami G, Scoccianti G, D'Arienzo A, Capanna R, Franchi A. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol. 2016;69:240–7.

    Article  CAS  Google Scholar 

  16. Sawyer JR, Goosen LS, Binz RL, Swanson CM, Nicholas RW. Evidence for telomeric fusions as a mechanism for recurring structural aberrations of chromosome 11 in giant cell tumor of bone. Cancer Genet Cytogenet. 2005;159:32–6.

    Article  CAS  Google Scholar 

  17. Gorunova L, Vult von Steyern F, Storlazzi CT, Bjerkehagen B, Follerås G, Heim S, Mandahl N, Mertens F. Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations. Genes Chromosomes Cancer. 2009;4:583–602.

    Article  Google Scholar 

  18. Moskovszky L, Szuhai K, Krenács T, Hogendoorn PC, Szendroi M, Benassi MS, Kopper L, Füle T, Sápi Z. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer. 2009;48:468–79.

    Article  CAS  Google Scholar 

  19. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479–82.

    Article  CAS  Google Scholar 

  20. Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, Jundt G, Hamoudi R, Wedge DC, Loo PV, Hassan AB, Khatri B, Ye H, Tirabosco R, Amary MF, Flanagan AM. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1:113–23.

    Article  CAS  Google Scholar 

  21. Cleven AH, Höcker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovée JV. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39:1576–83.

    Article  Google Scholar 

  22. Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, Gibbons R, Tirabosco R, O’Donnell P, Flanagan AM. H3F3A (histone 3.3) G34W immunohistochemistry: a reliable marker defining benign and malignant giant cell tumor of bone. Am J Surg Pathol. 2017;41:1059–68.

    Article  Google Scholar 

  23. Righi A, Mancini I, Gambarotti M, Picci P, Gamberi G, Marraccini C, Dei Tos AP, Simi L, Pinzani P, Franchi A. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. Hum Pathol. 2017;68:128–35.

    Article  CAS  Google Scholar 

  24. Divisato G, Scotto di Carlo F, Pazzaglia L, Rizzo R, Coviello DA, Benassi MS, Picci P, Esposito T, Gianfrancesco F. The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences. Oncotarget. 2017;8:63121–31.

    Article  Google Scholar 

  25. Lüke J, von Baer A, Schreiber J, Lübbehüsen C, Breining T, Mellert K, Marienfeld R, Schultheiss M, Möller P, Barth TFE. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology. 2017;71:125–33.

    Article  Google Scholar 

  26. Conti A, Rodriguez GC, Chiechi A, Blazquez RM, Barbado V, Krènacs T, Novello C, Pazzaglia L, Quattrini I, Zanella L, Picci P, De Alava E, Benassi MS. Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis. Am J Pathol. 2011;178:88–97.

    Article  CAS  Google Scholar 

  27. Balla P, Moskovszky L, Sapi Z, Forsyth R, Knowles H, Athanasou NA, Szendroi M, Kopper L, Rajnai H, Pinter F, Petak I, Benassi MS, Picci P, Conti A, Krenacs T. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. Histopathology. 2011;59:376–89.

    Article  Google Scholar 

  28. Shalini S, Singh M, Mak IW, Turcotte R, Ghert M. Investigation of FGFR2-IIIC signaling via FGF-2 ligand for advancing GCT stromal cell differentiation. PLoS One. 2012;7:e46769.

    Article  Google Scholar 

  29. Quattrini I, Pollino S, Pazzaglia L, Conti A, Novello C, Ferrari C, Pignotti E, Picci P, Benassi MS. Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study. J Orthop Res. 2015;33:1205–11.

    Article  CAS  Google Scholar 

  30. Mosakhani N, Pazzaglia L, Benassi MS, Borze I, Quattrini I, Picci P, Knuutila S. MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. Histol Histopathol. 2013;28:671–8.

    PubMed  Google Scholar 

  31. Conti A, Fredolini C, Tamburro D, Magagnoli G, Zhou W, Liotta LA, Picci P, Luchini A, Benassi MS. Identification of novel candidate circulating biomarkers for malignant soft tissue sarcomas: correlation with metastatic progression. Proteomics. 2016;16:689–97.

    Article  CAS  Google Scholar 

  32. Conti A, Luchini A, Benassi MS, Magagnoli G, Pierini M, Piccinni-Leopardi M, Quattrini I, Pollino S, Picci P, Liotta LA, Pazzaglia L. Circulating candidate biomarkers in giant cell tumors of bone. Proteomics Clin Appl. 2018;12(6):1800041.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

    Maria Serena Benassi

Authors
  1. Maria Serena Benassi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. I.S.G. Italian Sarcoma Group, Bologna, Italy

    Piero Picci

  2. IIIrd Clinic of Orthopaedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy

    Marco Manfrini

  3. Istituto Ortopedico Rizzoli, Bologna, Italy

    Davide Maria Donati

  4. Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

    Marco Gambarotti

  5. Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

    Alberto Righi

  6. Istituto Rizzoli, Bologna, Italy

    Daniel Vanel

  7. Department of Medicine, University of Padua School of Medicine, Padua, Italy

    Angelo Paolo Dei Tos

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Benassi, M.S. (2020). Biology of Giant Cell Tumour. In: Picci, P., et al. Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions. Springer, Cham. https://doi.org/10.1007/978-3-030-29676-6_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-29676-6_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-29675-9

  • Online ISBN: 978-3-030-29676-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation